Introduction
============

Hypertension is one of the leading risk factors for developing cerebrovascular disease, stroke, myocardial infarction, congestive heart failure, renal disease, and peripheral vascular disease.[@B1] Cerebrovascular disease is the second most prevalent disease after cancer, and is the greatest cause of mortality in Korea. In addition, patients with cerebrovascular disease are burdened with socio-economic problems, particularly following the acute medical event. In fact, medical costs due to cerebrovascular disease accounted for 5% of the 2010 total health care costs.[@B2]

According to the 2010 Korea National Health and Nutrition Examination Survey, the recognition, treatment, and control of hypertension patients was 67.9%, 61.9% and 69.7%, respectively.[@B3] Health insurance fees in 2010 were estimated to be approximately \$1.96 billion for patients with hypertension.[@B4] In particular, anti-hypertensive drug costs, based on outpatient prescriptions, were estimated to be approximately \$1.47 billion.[@B5]

Hypertension is one of the diseases with which Koreans are greatly burdened, and it has been reported to have a significant effect on their overall medication adherence (MA), hospitalization rates, number of visits to an emergency department, and the natural history of other conditions.[@B6] This has led to the speculation that MA and anti-hypertensive pharmacological treatments may be useful in preventing the occurrence of complications and in successfully controlling blood pressure.[@B7]

According to studies that have been conducted to examine MA, anti-hypertensive treatments are effective in the primary prevention of both hemorrhagic and ischemic strokes (relative risk decreased by 35-45%).[@B8] Additionally, a meta-analysis of randomized controlled trials using antihypertensive agents found a 20-30% reduction in stroke risk when there was a 1-3 mmHg decrease in systolic blood pressure.[@B8]

Furthermore, hypertensive patients with an MA of \<80% were at a 2.38 times higher risk of hospitalization compared to those whose MA was ≥80%.[@B9] Moreover, patients with a greater anti-hypertensive MA, who presented with complications, incurred lower medical costs.[@B10]

MA is essential for not only for managing patients with hypertension but also for preventing the occurrence of complications. Therefore, we measured health outcomes according to the level of MA, analyzed the incidence of complications in patients with good MA, and clarified the effects that might affect MA. We attempted to identify the relationship between level of MA and complication incidence among new hypertensive patients in Korea.

Subjects and Methods
====================

Study population
----------------

We defined the study patients using claims data from the National Health Insurance Service (NHIS), which collected health utilization on a nationwide scale. Korea\'s National Health Insurance (NHI) system manages mandatory universal health insurance. The Korean NHI claims database contains information on the entire population covered by the health insurance system and is nationally representative of all medical and prescription drug claims records.[@B11][@B12] We used this data to identify patients with hypertension.

The inclusion criteria were as follows:

\(1\) patients with hypertension whose major diagnoses included ICD-10 code: I10-I15, excluding I14

\(2\) patients aged 20 years or older

\(3\) patients with newly diagnosed hypertension who have not used medical services for the past year

\(4\) patients who filed claims for health insurance coverage for hypertension more than once in the year 2008

\(5\) patients who were prescribed anti-hypertensive drugs at least once.

The date of the first prescription (index date) was defined as that when the study patients were first prescribed with anti-hypertensive drugs in 2008

The exclusion criteria for the current study were as follows:

\(1\) patients with newly diagnosed hypertension who died within two years after they received their first prescription

\(2\) patients who suffered complications such as stroke or ischemic heart disease within one year before medication was first prescribed and two years following the first prescription; the purpose of this criterion was to identify the association between the MA of newly hypertensive patients and complication incidence during the 2-year follow-up.[@B13]

We also defined patients who were in need of anti-hypertensive pharmacological treatment as those who had been given anti-hypertensive agents for more than 14 days over the past six months.[@B10]

Study design
------------

Data from January 1, 2007 to December 31, 2011 were used in this retrospective cohort study. We also performed follow-up for up to three years, depending on the cohorts. The 3-year follow-up period was composed of a 2-year period, where the MA was evaluated based on the index date when patients initially used the anti-hypertensive medical service treatments as well as a 1-year period where treatment outcomes, such as complications, were evaluated. In the present study, the same length of time was applied to all patients, but there was variability in the accuracy of the length of follow-up period depending on the patients. For instance, if patients were first diagnosed with hypertension on January 1, 2008, they would be followed up with until December 31, 2010. In addition, if they were first diagnosed with hypertension on June 1, 2008, the follow-up period lasted until June 30, 2011.

Measures
--------

### Independent variable: medication adherence

MA is defined as the degree to which patients adhere to the drugs that have been prescribed for them by their physicians.[@B7] Indicators of MA include the medication possession ratio (MPR), medication adherence rating, cumulative medication adherence, and proportion of days covered. Of these, the MPR is based on billing claims data and is useful in evaluating MA in patients with chronic diseases.[@B13] We therefore measured the MPR using in-hospital and hospital pharmacy dispensing data.

MPR was calculated as the proportion of the number of days of the drug was used following its prescription out of the total number of days accounted for by the prescription end date.[@B14] The MPR measurement period was established as 2 years from the date of the first prescription, since this time period was similar to that in which the MA was measured. MPR was calculated for each patient according to the following formula:

MPR (%)=(the total number of days of prescription treatment during the follow-up period/the length of the follow-up period, ranging from prescription beginning to end date)×100

Where the total number of days of prescription treatment was greater than the length of the follow-up period, all the MPRs indicating \>100% were considered to be 100%. In addition, the simultaneous prescription of multiple anti-hypertensive treatment agents was defined as concomitant medication. In these cases, the number of the days of prescription was defined as the maximal value, with adjustments made for variability.[@B10]

MPR was classified into five categories: 0-19%, 20-39%, 40-59%, 60-79%, and 80-100%. As previously reported, depending on an MPR cut-off value of 80%, the study patients were assigned to either the MA (MPR≥80%) or non-MA group (MPR\<80%).[@B15]

Anti-hypertensive treatment agents were classified into 12 groups based on a list of drugs that were covered by health insurance as of July 2011, with reference to the World Health Organization Anatomical Therapeutic Chemical classification system ([Supplementary Table](#S1){ref-type="supplementary-material"} in the online-only Data Supplement).

### Covariates

To evaluate hypertension severity, we analyzed controlled variables, such as MA, the main types and location of medical institutions, Charlson Comorbidity Index (CCI) scores, history of hospitalization during the past year, and history of diabetes mellitus.

To evaluate the severity of disease depending on the number of anti-hypertensive treatment agents, we evaluated their constituents at the time of the first prescription as well as the medical institutions the study patients visited during the year following their first prescription (1, 2-3 and 4+), as surrogate variables.

### Dependent variables

In the present study, for complications of hypertension, we selected ischemic heart disease (ICD-10 code I20-I25) and cerebrovascular disease (ICD-10 code I60-I63).[@B16] Moreover, to include the incident case of complications arising from hypertension only, we used defined hospitalization due to complications as well as when individuals visited outpatient clinics for the management of corresponding morbidities as major diagnoses for more than three times or when they were hospitalized more than once.[@B10] MA was evaluated based on health outcomes, which was assessed according to the number of complications arising during the final year of the 3-year follow-up period.

Statistical analysis
--------------------

To identify the correlation between MA and complication incidence, based on sex, age, type of health insurance coverage, main types and locations of medical institutions, CCI scores, past history of hospitalization, and past history of diabetes mellitus, MPR mean and standard deviation were analyzed using Student\'s t-test and ANOVA. The MPR was classified into five categories, for which a Chi-squared test was performed to analyze the statistical significance of the MPR differences.

To compare complication incidence depending on MPR level, we controlled for possible confounding variables including sex, age, and type of health insurance coverage, main types and locations of medical institutions, CCI scores, a past history of hospitalization or diabetes, the number of prescribed drugs taken, and the number of medical institutions visited during the first year. Subsequently, we performed an analysis using Cox\'s proportional hazards model, for which we defined the time to event as the length of the period extending from the index date to the date at which medical services were used to treat complications. All statistical analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). The level of statistical significance was determined as below 5%. The study was approved by the Institutional Review Board of Korea University (1040548-KU-IRB-13-164-A-1).

Results
=======

Baseline and clinical characteristics of the patients
-----------------------------------------------------

In 2008, a total of 4294773 patients were diagnosed with hypertension and were prescribed anti-hypertensive medications. Of these, 985722 were classified as newly hypertensive patients. In the present study, we enrolled 564782 patients (who met the inclusion/exclusion criteria ([Fig. 1](#F1){ref-type="fig"}).

![Study population dataset for continuity of care.](kcj-46-384-g001){#F1}

The number of newly-diagnosed patients who underwent treatment in 2008 was 564782, and there were slightly more females treated than males (52.6% vs*.* 47.5%). The mean age of the study patients was 58.8 years. The proportion of study patients in each age group was as follows: 50-59 years: 26.4%, 60-69 years: 25.2%, and 40-49 years: 19.7%. The overwhelming majority (92.9%) of patients had health insurance.

Concerning the treatment facilities, most patients (67.7%) were seen at local clinics, followed by 14.0% at public health centers, and 10.6% at specialized and general hospitals. Just under half of these facilities (45.2%) were located in metropolitan areas, 43.0% were in small urban areas, and 11.8% were in rural districts. The breakdown of patients\' CCI scores was as follows: 0 points (58.5%), 1 point (25.2%), 2 points (9.9%), and 3 points (6.4%).

The proportion of patients who were hospitalized during the first year prior to the time of the first prescription was 1.1%. The proportion of patients with a past history of diabetes was 12.1%. The proportions of anti-hypertensive drug constituents at the time of first prescription date were as follows: 1 (69.2%), 2 (25.6%), and more than 3 (5.2%). In addition, the number of medical institutions used by the patients during the first year of follow-up is shown in [Table 1](#T1){ref-type="table"}. Most patients (82.1%) used only one institution during their first year of follow up.

###### General characteristics of patients with newly-diagnosed hypertension
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  Parameters                                            Total       Complications^\*^   No complications^\*^                   
  ----------------------------------------------------- ----------- ------------------- ---------------------- ------ -------- ------
  Gender                                                                                                                       
   Male                                                 267965      47.5                4144                   48.0   263821   47.4
   Female                                               296817      52.6                4485                   52.0   292332   52.6
  Age (mean±SD)                                         58.8±13.0   65.2±11.8           58.7±13.0                              
   20-29                                                4502        0.8                 11                     0.1    4491     0.8
   30-39                                                31806       5.6                 140                    1.6    31666    5.7
   40-49                                                111284      19.7                795                    9.2    110489   19.9
   50-59                                                148927      26.4                1690                   19.6   147237   26.5
   60-69                                                142564      25.2                2596                   30.1   139968   25.3
   70-79                                                94199       16.7                2498                   29.0   91701    16.5
   80-89                                                28811       5.1                 839                    9.7    27972    5.0
   90+                                                  2689        0.5                 60                     0.7    2629     0.5
  Insurance type                                                                                                               
   Health insurance                                     524859      92.9                7582                   87.9   517277   93.0
   Medical aid                                          39923       7.1                 1047                   12.1   38876    7.0
  Main attending medical institution                                                                                           
   Specialized & general hospital                       59917       10.6                1237                   14.3   58680    10.6
   Hospital                                             38582       6.8                 681                    7.9    37901    6.8
   Clinic                                               382124      67.7                5261                   61.0   376863   67.8
   Public center                                        78859       14.0                1360                   15.8   77499    13.9
   No main attending medical institution                5300        0.9                 90                     1.0    5210     0.9
  Residence                                                                                                                    
   Metropolitan city                                    255377      45.2                3613                   41.9   251764   45.2
   Small urban region                                   242744      43.0                3754                   43.5   238990   43.0
   Rural district                                       66661       11.8                1262                   14.6   65399    11.8
  CCI                                                                                                                          
   0                                                    330273      58.5                4216                   48.9   326057   58.6
   1                                                    142408      25.2                2388                   27.7   140020   25.2
   2                                                    55615       9.9                 1103                   12.8   54512    9.8
   3+                                                   36486       6.4                 922                    10.6   35564    6.4
  History of hospitalization                                                                                                   
   No                                                   558682      98.9                8475                   98.2   550207   98.9
   Yes                                                  6100        1.1                 154                    1.8    5946     1.1
  DM                                                                                                                           
   No                                                   496142      87.9                6933                   80.4   489209   88.0
   Yes                                                  68640       12.1                1696                   19.6   66944    12.0
  No. of antihypertensive drugs on the index date                                                                              
   1                                                    390489      69.2                5348                   62.0   385141   69.2
   2                                                    144687      25.6                2531                   29.3   142156   25.6
   3+                                                   29606       5.2                 750                    8.7    28856    5.2
  No. of attending medical institution for 1~st~ year                                                                          
   1                                                    463646      82.1                6898                   79.9   456748   82.1
   2-3                                                  100591      17.8                1718                   19.9   98873    17.8
   4+                                                   545         0.1                 13                     0.2    532      0.1

^\*^Complications represent both ischemic heart disease and stroke. SD: standard deviation, CCI: Charlson Comorbidity Index, DM: diabetes mellitus

Concerning changes in MA based on patient characteristics, the level of MA was 77.0% in men, which was relatively higher than that of women. In addition, mean MPR was greater in the older age group (77.9% in the 50-59-year-old group being the highest) as compared to the younger age group. Additionally, mean MPR was the highest in patients who used health insurance. Most (82.6%) of the patients visited public health centers, while 77.0% used specialized and general hospitals and 76.0% used local clinics. Mean MPR was relatively higher among patients who used medical institutions in metropolitan cities, those who had no past history of hospitalization, and those who had no past history of diabetes ([Table 2](#T2){ref-type="table"}). During the 3 years of follow up, 1.5% of the study sample developed complications. The incidence of cardiovascular complications was 0.1%, 0.2%, 0.2%, 0.3%, and 0.8% among the participants with MPRs of 0-19%, 20-39%, 40-59%, 60-79%, and 80-100%, respectively.

###### Medication possession ratio in patients newly diagnosed with hypertension in 2008
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  Parameters                                            MPR (%)                          0-19        20-39   40-59   60-79   80-100                                               
  ----------------------------------------------------- -------------------------------- ----------- ------- ------- ------- -------- ------- -------- -------- -------- -------- ------
  Total                                                 76.5±24.6                        19845       3.5     43940   7.8     68968    12.2    106244   18.8     325785   57.7     
  Gender                                                Male                             77.0±24.5   9449    3.5     20000   7.5      31459   11.7     49088    18.4     157969   59.0
  Female                                                76.0±24.6                        10396       1.8     23940   8.1     37509    12.6    57156    19.4     167816   56.5     
  Age                                                   20-29                            69.3±27.9   337     7.5     494     11.0     683     15.1     922      20.5     2066     45.9
  30-39                                                 73.0±25.6                        1488        4.7     2973    9.4     4354     13.7    6694     21.1     16297    51.2     
  40-49                                                 76.2±24.3                        3973        3.6     8351    7.5     13400    12.0    22188    19.9     63372    57.0     
  50-59                                                 77.9±23.6                        4344        2.9     10235   6.9     16992    11.4    27657    18.6     89699    60.2     
  60-69                                                 77.8±24.1                        4438        3.1     10418   7.3     16561    11.6    25328    17.8     85819    60.2     
  70-79                                                 75.5±25.4                        3723        4.0     8109    8.6     12289    13.1    17286    18.4     52792    56.0     
  80-89                                                 72.3±26.4                        1405        4.9     3054    10.6    4243     14.7    5608     19.5     14501    50.3     
  90+                                                   70.3±26.5                        137         5.1     306     11.4    446      16.6    561      20.9     1239     46.1     
  Insurance type                                        Health insurance                 76.8±24.4   17867   3.4     39544   7.5      63061   12.0     98336    18.7     306051   58.3
  Medical aid                                           71.8±26.5                        1978        5.0     4396    11.0    5907     14.8    7908     19.8     19734    49.4     
  Main attending medical institution                    Specialized & general hospital   77.0±25.0   1969    3.3     5003    8.4      7617    12.7     10204    17.0     35124    58.6
  Hospital                                              70.6±25.1                        1695        4.4     4103    10.6    6033     15.6    9060     23.5     17691    45.9     
  Clinic                                                76.0±24.6                        13651       3.6     30436   8.0     47636    12.5    73347    19.2     217054   56.8     
  Public center                                         82.6±20.9                        1285        1.6     3577    4.5     6945     8.8     12898    16.4     54154    68.7     
  No main attending medical institution                 54.8±34.3                        1245        23.5    821     15.5    737      13.9    735      13.9     1762     33.3     
  Residence                                             Metropolitan city                77.6±24.1   8129    3.2     18511   7.3      29698   11.6     46662    18.3     152377   59.7
  Small urban region                                    76.2±24.7                        8846        3.6     19067   7.9     29829    12.3    46341    19.1     138661   57.1     
  Rural district                                        73.4±25.6                        2870        4.3     6362    9.5     9441     14.2    13241    19.9     34747    52.1     
  CCI                                                   0                                75.4±25.4   14216   4.3     27354   8.3      41233   12.5     61604    18.7     185866   56.3
  1                                                     78.1±23.4                        3581        2.5     10139   7.1     16587    11.7    26654    18.7     85447    60.0     
  2                                                     77.9±23.4                        1336        2.4     4040    7.3     6665     12.0    10568    19.0     33006    59.4     
  3+                                                    78.1±22.5                        712         2.0     2407    6.6     4483     12.3    7418     20.3     21466    58.8     
  History of hospitalization                            No                               76.5±24.5   19457   3.5     43186   7.7      68058   12.2     105042   18.8     322939   57.8
  Yes                                                   69.9±27.7                        388         6.4     754     12.4    910      14.9    1202     19.7     2846     46.7     
  DM                                                    No                               77.2±24.2   16378   3.3     36017   7.3      58446   11.8     92690    18.7     292611   59.0
  Yes                                                   71.2±26.7                        3467        5.1     7923    11.5    10522    15.3    13554    19.8     33174    48.3     
  No. of antihypertensive drugs on the index date       1                                76.0±24.8   14468   3.7     31058   8.0      48450   12.4     74460    19.1     222053   56.9
  2                                                     77.4±24.0                        4473        3.1     10726   7.4     17070    11.8    26542    18.3     85876    59.4     
  3+                                                    78.0±24.1                        904         3.1     2156    7.3     3448     11.7    5242     17.7     17856    60.3     
  No. of attending medical institution for 1~st~ year   1                                77.3±24.3   15044   3.2     34871   7.5      54475   11.8     84524    18.2     274732   59.3
  2\~3                                                  72.9±25.6                        4778        4.8     9016    9.0     14395    14.3    21565    21.4     50837    50.5     
  4+                                                    69.7±24.6                        23          4.2     53      9.7     98       18.0    155      28.4     216      39.6     

MPR: medication possession ratio, SD: standard deviation, CCI: Charlson Comorbidity Index, DM: diabetes mellitus

To examine the risk of developing complications based on MA level, we applied Cox\'s proportional hazards model ([Table 3](#T3){ref-type="table"}). There was a 1.36 times higher risk of developing complications in the 40-59% MPR group (95% confidence interval \[CI\]: 1.27-1.45) compared to the MA group (MPR≥80%) and a 2.01 times higher risk of developing complications in the \<20% MPR group (95% CI: 1.82-2.23). Overall, those who had a poorest MA were at the highest risk of developing complications.

###### Multivariable-adjusted hazard ratios for the association between medication possession ratio and complication rate among patients with newly-diagnosed hypertension
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  Parameters                                                                 HR^\*^   (95% CI)       p
  -------------------------------------------------------------------------- -------- -------------- ----------
  MPR (ref.: 80-100%)                                                                                
   0-19                                                                      2.01     (1.82-2.23)    \<0.0001
   20-39                                                                     1.60     (1.48-1.72)    \<0.0001
   40-59                                                                     1.36     (1.27-1.45)    \<0.0001
   60-79                                                                     1.14     (1.08-1.21)    \<0.0001
  Gender (ref.: male)                                                                                
   Female                                                                    0.72     (0.69-0.76)    \<0.0001
  Age (ref.: 20-29)                                                                                  
   30-39                                                                     1.30     (0.70-2.39)    0.4077
   40-49                                                                     2.00     (1.10-3.62)    0.0227
   50-59                                                                     3.17     (1.75-5.74)    0.0001
   60-69                                                                     5.10     (2.82-9.23)    \<0.0001
   70-79                                                                     7.63     (4.22-13.81)   \<0.0001
   80-89                                                                     10.02    (5.52-18.17)   \<0.0001
   90+                                                                       10.76    (5.65-20.48)   \<0.0001
  Insurance type (ref.: health insurance)                                                            
   Medical aid                                                               1.45     (1.35-1.55)    \<0.0001
  Main attending medical institution(ref.: specialized & general hospital)                           
   Hospital                                                                  0.70     (0.63-0.77)    \<0.0001
   Clinic                                                                    0.55     (0.52-0.59)    \<0.0001
   Public center                                                             0.51     (0.47-0.55)    \<0.0001
   No main attending medical institution                                     0.82     (0.66-1.02)    0.0787
  Residence (ref.: metropolitan city)                                                                
   Small urban region                                                        1.07     (1.02-1.12)    0.0032
   Rural district                                                            1.09     (1.02-1.17)    0.0100
  CCI (ref.: 0)                                                                                      
   1                                                                         1.16     (1.10-1.22)    \<0.0001
   2                                                                         1.27     (1.19-1.37)    \<0.0001
   3+                                                                        1.49     (1.38-1.61)    \<0.0001
  History of hospitalization (ref.: no)                                                              
   Yes                                                                       1.20     (1.02-1.41)    0.0276
  DM (ref.: no)                                                                                      
   Yes                                                                       1.80     (1.70-1.91)    \<0.0001
  No. of antihypertensive drugs on the index date (ref.: 1)                                          
   2                                                                         1.12     (1.07-1.17)    \<0.0001
   3+                                                                        1.44     (1.33-1.56)    \<0.0001
  No. of attending medical institution for 1~st~ year (ref.: 1)                                      
   2-3                                                                       1.00     (0.95-1.06)    0.9132
   4+                                                                        1.28     (0.74-2.21)    0.3700

**^\*^**Cox\'s proportional hazards model: adjusted for gender, age (20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, and ≥90 years), the type of health insurance coverage (health insurance or medical aid), the main types of medical institutions (specialized or general hospitals, hospitals, local clinics, public health centers, and non-applicable), the location of medical institutions (metropolitan city, small urban areas, and rural districts), CCI (0, 1, 2, and ≥3), past history of hospitalization (yes or no) and diabetes mellitus (yes or no), the number of anti-hypertensive drugs on the index date (1, 2, and ≥3), and the number of medical institutions for the 1st one year (1, 2-3, and ≥4). HR: hazard ratio, CI: confidence interval, MPR: medication possession ratio, ref.: reference, CCI: Charlson Comorbidity Index, DM: diabetes mellitus

The risk of developing complications was higher with increasing patient age. As compared to patients in their 20\'s, the complication risk was double that for those in their 40 s and was 7.63 times higher for those in their 70 s. Importantly, the risk of developing complications was 1.45 times higher among those who did not have health insurance. The risk of developing complications was lower among patients who mainly used hospitals, local clinics, and public health centers compared to those who used specialized or general hospitals. With respect to the location of medical institutions, as compared with metropolitan cities, the risk of developing complications among patients at medical institutions in small urban cities and rural districts was 1.07 and 1.09 times greater, respectively. As compared to patients with a CCI score of 0, the risk of developing complications was 1.49 times greater among those whose CCI scores were 3 points. In patients who had a past history of hospitalization or diabetes mellitus over the past year, the risk of developing complications was 1.20 and 1.80 times higher, respectively. Among patients taking more than 3 different anti-hypertensive medicines at the time of the first prescription date, the risk of developing complications was 1.44 times greater, as compared to those who took only 1 anti-hypertensive drug at that time.

Discussion
==========

In the present study, MA was relatively higher in men compared to women as well as among the 50-59 year-old age group. MA was lower, however, for those in the older age groups. In addition, higher rates of MA was associated with having health insurance services, public health centers located in metropolitan cities, more than three therapeutic agents at the time of the first prescription, and a smaller number of medical institutions visited during the first year after prescription.

According to a study using the Ontario Prescription Database with newly hypertensive patients, the 1-year and 2-year MPRs were 73% and 66%, respectively, both of which were slightly lower, compared to our results.[@B17] In addition, according to a previous study that was conducted among newly hypertensive patients in 2006, the mean MPR value was 76.4%. The proportion of the patients in the MA group was 52.9%.[@B18] This discrepancy may be due to baseline differences between the study populations, definition, data, the types of prescribed drugs, and methods for measuring MA in the present and aforementioned studies. Although it is difficult to directly compare between previous reports and our results, the level of medication adherence among Korean hypertensive patients appears to be relatively higher, based on overall mean MPR.

Of the factors that may affect MA, older age (up to the age of 60 years) was associated with improved adherence to antihypertensive medications. This is consistent with previous reports. According to a study conducted among individuals from Gwacheon, medication adherence was relatively higher in the 50-59-years-old age group, followed by the 60-69-years-old group. In addition, it was the lowest among those between the ages of 40 and 49.[@B19] According to previous reports, both MA and continuity of care were lower for younger patients.[@B20] Moreover, in the present study, the mean MPR was 69.31% for those between the ages of 20 and 29 years old, which was the lowest among all groups. However, the degree of MA was lowest among those aged 60 and older.

This was may be due to the following reasons:

\(1\) Most of the elderly received multiple medications due to the presence of one or more comorbidity.

\(2\) The age-related decrease in psychomotor abilities and decreased independence in completing daily activities eventually leads to decreased MA levels.

\(3\) In the presence of pharmaceutical treatment for chronic diseases other than hypertension anti-hypertensive treatment agents, it is often more difficult for patients to take the anti-hypertensive treatment agents as well.[@B21]

It can, therefore, be quite reasonably assumed that the degree of MA would be lower among those aged 60 and older.[@B21]

As CCI scores increased, the level of MA also increased. Moreover, previous studies have shown that the degree of MA was relatively higher among patients who concurrently suffered from cardiovascular diseases or diabetes.[@B22] In addition, a past history of angina pectoris or myocardial infarction had a positive effect (improved) on MA.[@B23] The level of MA was higher among patients who used health insurance services, an observation that is in keeping with findings from previous studies. This may, in part, be due to the cost of anti-hypertensive medications. However, for Medical aid in Korea, out-of-pocket payment is low; thus, the economic burden for Medical aid is relatively small.[@B24]

However, prior studies have reported that cost-related non-adherence is prevalent among patients with mood disorders and those who have greater disease burden, irrespective of drug coverage status, poverty level, or out-of-pocket drug costs.[@B25] Thus, one may speculate that high disease burden can contribute to lower MA.

Previous studies have shown that MA increased when there was a greater number of treatment agents, which is consistent with our results.[@B26] Further studies are warranted, however, to examine differences depending on the constituents of treatment agents because there was a significant difference in MA.

The risk of developing complications was 1.36 times higher (95% CI: 1.27-1.45) in the MA group (MPR≥80%) compared to the MPR 40-59%. When MPR was lower than 20%, the complication risk was 2.01 times higher (95% CI: 1.82-2.23). Taken together, these findings indicate that patients with a lower MA are at a higher risk of developing complications.

In patients with a lower MA for anti-hypertensive drugs, the incidence of cerebrovascular disease was significantly increased, leading to a direct increase in overall medical costs. According to a study conducted among newly hypertensive patients, there was an increase in the risk of developing coronary artery diseases, cerebrovascular disease, and congestive heart failure by 1.07, 1.13, and 1.42 times, respectively, in the non-MA group (MPR\<80%).[@B27] In addition, according to a study conducted in Australia, there was a lower risk of developing a first, or fatal, cerebrovascular disease event in the MA group (MPR\>80%) by 0.81 times and a 0.58 times decreased risk of cardiac failure compared to the non-MA group.[@B28] These findings are in keeping with our results. Based on these findings, there may be an increased risk of developing complications when there is a reduction in anti-hypertensive MA followed by increased hospitalization and mortality. Further studies are therefore warranted to reduce the risk of developing complications by raising the MA for anti-hypertensive drugs.

There are several limitations to the current study. First, we analyzed the NHIS data and did not completely consider patient-related characteristics, such as economic status and health-seeking behavior. In particular, although there is a close relationship between the economic status of the patients and their health-seeking behaviors, we did not consider it due to a limited amount of available data. To resolve this, we used the main types of medical institutions as surrogate variables. In addition, as the surrogate variables are indicative of the severity of hypertension, an examination of risk factors associated with the occurrence of complications, such as a past history of smoking, serum cholesterol levels, blood pressure, and obesity were also needed. However, these key risk factor data are not documented in the NHIS database. We therefore analyzed surrogate variables that are indicative of hypertension severity, such as a past history of hospitalization, the frequency of visits to the outpatient desk of a clinical department, CCI scores, and a past history of diabetes. However, because we did not adjust the characteristics of patients such as hypertension, hyperlipidemia and obesity directly, the effect of MA may be overestimated in this study. Therefore, further studies are warranted to identify the relationship between MA and health outcomes.

In addition, we measured medication adherence indirectly from administrative claims data using MPR. MPR is an indirect method for calculating adherence based on billing claims data. According to the MPR formula, it is necessary to hypothesize that the number of days since the time of the prescription is exactly the same as the number of days during which the patients actually took the drugs. It is certainly possible that there may be a difference between the records of long-term administration of drugs and their actual records. Nevertheless, the MPR mode was used to easily evaluate the status of MA in patients with chronic diseases and enabled comparison with the results of other studies. Therefore, to assess compliance to anti-hypertensive medications using retrospective data, MPR may be the best predictive measure.[@B13]

Our results indicate that MA affected health outcomes due to hypertension in hypertensive patients. In newly hypertensive patients, assessing MA may be one of the strategies for reducing the risks of developing cerebrovascular disease complications. Moreover, it could also be used as an alternative for preventing long-term loss of productivity due to medical costs and disability arising from cerebrovascular disease.

Various policy-based approaches are essential for strengthening MA for the purposes of controlling hypertension in a patient-customized manner. In particular, our results showed there was a close relationship between MA and health outcomes in newly hypertensive patients and in those who were in need of primary medical services. These findings suggest that the current system used to manage chronic diseases should be strengthened by the development of polices that enable continuing therapy by primary care physicians.[@B20]

Finally, factors that may interfere with MA include psychological factors such as depression, patients\' attitudes toward treatment, complex drug therapy, amnesia, and decreased social support. Therefore, healthcare providers should maintain a continuous relationship between patients and physicians and should provide consultation for them on a regular basis. This should also be accompanied by the preparation of a policy establishing healthcare promotion medical fees and incentive payments for the purpose of compensating the efforts of medical institutions on a nationwide scale. Furthermore, by reducing unnecessary in-hospital treatments through the promotion of patient health, medical costs arising from complications may decrease in the long term.

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C0729).

Supplementary Materials
=======================

The online-only Data Supplement is available with this article at <http://dx.doi.org/10.4070/kcj.2016.46.3.384>.

###### Supplementary Table

Anti-hypertensive agents and constituents
